Multimodal Combination Therapy Register

PROBLEM: The review's central finding is synergy: hafnium radiosensitizers work best combined — radiotherapy plus photodynamic therapy, chemotherapy, or immunotherapy. Each combination is a different risk profile: a photodynamic combination needs light dosimetry, a chemotherapy combination needs drug interaction data, an immunotherapy combination needs immune-monitoring data. But combination results are published as one-off papers, and there is no standing register of which combinations were tried, at what doses, with what measured synergy — so the same combination gets re-tested blind while a failed one gets retried.

SOLUTION: A multimodal combination therapy register: every Hf-based combination logged with its partner modality, its dosing, its measured synergy endpoint, and its safety signal — so the next combination starts from the record of the last one.

EVIDENCE BASIS: DOCUMENTED — Hf-based systems integrate radiotherapy with photodynamic, chemotherapeutic, or immunotherapeutic strategies for precise targeting and significantly enhanced antitumor responses (Chen et al., Biomaterials 2026, abstract). Sources: PubMed 41418721.